Cancer drug keytruda a new weapon against advanced lung tumors

June 4, 2018 by Dennis Thompson, Healthday Reporter

(HealthDay)—A cancer drug that boosts the immune system outperforms chemotherapy in fighting advanced lung cancer, a new trial shows.

Keytruda (pembrolizumab) extended life four to eight months longer than chemotherapy in whose immune systems had been duped by their .

"This trial shows that pembrolizumab used alone improves survival as opposed to chemotherapy," said lead researcher Dr. Gilberto Lopes, a medical oncologist with the Sylvester Comprehensive Cancer Center at the University of Miami Health System.

But while Keytruda works better than chemotherapy, the combination of the two is likely to be the best first choice for treatment of lung cancer, Lopes added.

"We do believe based on a study presented about a month ago that the combination of chemotherapy plus pembrolizumab probably is better than pembrolizumab alone," Lopes said. "What we likely will see as the new standard of care is for us to combine both drugs."

Keytruda fights cancer by "taking the brakes away from the immune system so our own defense cells can recognize cancer cells and kill them," Lopes explained.

The drug has also worked well against other cancers. When former President Jimmy Carter was diagnosed with melanoma that had spread to his brain several years ago, it was Keytruda that threw the cancer into remission by curtailing the action of a protein known as PD-L1.

PD-L1 is found on cancer cells, and it essentially shoos away the immune system, fooling it into thinking that cancerous tissue is normal and healthy. Keytruda blocks that interference, allowing killer immune cells to find and destroy the cancer.

Usually, tumors with larger amounts of PD-L1 respond better to treatment with pembrolizumab. But some studies have shown that similar immunotherapies also have been effective against tumors with little or no detectable PD-L1, the researchers said in background notes.

To see just how effective pembrolizumab can be across the board, Lopes and his colleagues randomly assigned 1,274 patients with advanced lung cancer to receive either pembrolizumab or chemotherapy. Average follow-up time was almost 13 months.

The researchers found that anyone who received pembrolizumab had longer average survival than those who underwent chemotherapy, about 16.7 months versus 12 months.

But the benefits of pembrolizumab increased with the amount of PD-L1 expression in lung tumors:

  • Patients with PD-L1 in half of their tumors experienced 20 months average survival on pembrolizumab, compared to 12 months with chemotherapy.
  • Those with PD-L1 in 20 percent of tumors had 17.7 months average survival with pembrolizumab, compared with 13 months for chemotherapy.

"For all the three groups we studied, pembrolizumab led to longer survival and higher overall survival rates than chemotherapy alone," Lopes said.

The immunotherapy also proved to be a milder treatment than chemo. Only 18 percent of patients reported severe side effects with pembrolizumab, compared with 41 percent of patients on chemotherapy.

This would make pembrolizumab a strong option for older and sicker who can't safely handle the strain caused by chemo, said ASCO President Dr. Bruce Johnson, chief clinical research officer at the Dana-Farber Cancer Institute in Boston.

"You can give these therapies to people who are not feeling particularly well, because for most of the people it doesn't have the kind of side effects that come with chemotherapy," Johnson said.

Future studies will need to focus on how to best decide the right treatment for each patient, Lopes said.

"The big question now is who are the patients who might benefit from this alone, and those persons who might need and chemotherapy to have the best response," Lopes said.

Keytruda costs about $10,000 a month, Lopes said, in line with other newer drugs but more pricey than older drugs.

The study, funded by Keytruda manufacturer Merck, was scheduled for presentation Sunday at ASCO's annual meeting, in Chicago. Because they have yet to be published in a peer-reviewed medical journal, the findings should be considered preliminary.

Explore further: Combination therapy doubles survival in metastatic lung cancer

More information: Gilberto Lopes, M.D., medical oncologist, Sylvester Comprehensive Cancer Center, University of Miami Health System; Bruce Johnson, M.D., president, American Society of Clinical Oncology, and chief clinical research officer, Dana-Farber Cancer Institute, Boston; June 3, 2018, presentation, American Society of Clinical Oncology annual meeting, Chicago

The American Cancer Society has more about immunotherapy drugs to treat cancer.

Related Stories

Combination therapy doubles survival in metastatic lung cancer

April 16, 2018
The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to ...

ASCO: Pembrolizumab is good second-line Tx in urothelial CA

February 21, 2017
(HealthDay)—For patients with advanced urothelial cancer that has recurred or progressed after platinum-based chemotherapy, pembrolizumab is associated with increased overall survival, according to a study published online ...

Mature results favor pembrolizumab as second-line treatment for bladder cancer

September 11, 2017
Mature results from the KEYNOTE-045 trial to be presented today at the ESMO 2017 Congress in Madrid (1) have confirmed significantly longer survival in patients with advanced urothelial cancer who receive the checkpoint inhibitor ...

Adjuvant pembrolizumab beneficial in stage III melanoma

April 16, 2018
(HealthDay)—Pembrolizumab is associated with significantly longer recurrence-free survival than placebo as adjuvant therapy for high-risk stage III melanoma, according to a study published online April 15 in the New England ...

Immune therapy drug results in prolonged survival in advanced lung cancer

December 21, 2015
A Yale-led international study in patients with advanced non-small cell lung (NSCLC) cancer resistant to chemotherapy has found a promising weapon in an immune therapy drug commonly used to treat other cancers. The findings ...

Pembrolizumab new option in one-line treatment of adv lung cancer and high PD-L1 expression

October 11, 2016
Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial presented at the ESMO 2016 ...

Recommended for you

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.